Shopping Cart
- Remove All
- Your shopping cart is currently empty
Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb/IIIa, vitronectin and Mac-1 receptors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $213 | In Stock | |
5 mg | $563 | In Stock | |
10 mg | $886 | In Stock | |
25 mg | $1,330 | In Stock | |
50 mg | $1,780 | In Stock | |
100 mg | $2,430 | In Stock |
Description | Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leukocyte adhesion, acting by binding to glycoproteins IIb/IIIa, vitronectin and Mac-1 receptors. |
In vitro | Inhibiting platelet aggregation induced by physiologic and pathologic agonists, abciximab (C7E3) achieves this effect by binding to the platelet αIIbβ3 integrin[2]. Abciximab appears to have similar affinity for the αIIbβ3 and αvβ3 integrins and redistributes between them[2]. |
In vivo | Effectively preventing neointimal hyperplasia, abciximab (C7E3) is administered at a dose of 0.25 mg/kg/day via intravenous infusion for 28 days[2]. |
Alias | C7E3 |
Molecular Weight | 95.18 kDa |
Cas No. | 143653-53-6 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.